FOLFOX4 feasible first-line therapy for advanced gastric cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1498, 2005-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Adding cytokine-induced killer (CIK) cell therapy to the FOLFOX4 regimen is beneficial for treating advanced gastric cancer

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Anastrozole: first-line therapy for advanced breast cancer?

Inpharma, Vol. 1, Iss. 1270, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Capecitabine monotherapy is an effective and well tolerated first-line treatment for patients with advanced or metastatic gastric cancer

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite